SG11201407184PA - Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals - Google Patents
Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticalsInfo
- Publication number
- SG11201407184PA SG11201407184PA SG11201407184PA SG11201407184PA SG11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceuticals
- preparing
- derivatives
- chromen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1737CH2012 | 2012-05-04 | ||
| US201261671956P | 2012-07-16 | 2012-07-16 | |
| PCT/IB2013/053544 WO2013164801A1 (en) | 2012-05-04 | 2013-05-03 | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407184PA true SG11201407184PA (en) | 2014-12-30 |
Family
ID=54193684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407184PA SG11201407184PA (en) | 2012-05-04 | 2013-05-03 | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9309216B2 (zh) |
| EP (1) | EP2844647B1 (zh) |
| JP (2) | JP6290186B2 (zh) |
| KR (1) | KR102073181B1 (zh) |
| CN (2) | CN104507922B (zh) |
| AP (1) | AP3547A (zh) |
| AU (1) | AU2013255469B2 (zh) |
| BR (1) | BR112014027470A2 (zh) |
| CA (1) | CA2871000C (zh) |
| CL (1) | CL2014002986A1 (zh) |
| CO (1) | CO7141413A2 (zh) |
| CY (1) | CY1123456T1 (zh) |
| EA (1) | EA032812B1 (zh) |
| HK (1) | HK1203964A1 (zh) |
| IL (1) | IL235181A (zh) |
| MX (1) | MX365250B (zh) |
| MY (1) | MY171207A (zh) |
| NZ (1) | NZ701198A (zh) |
| PH (1) | PH12014502453A1 (zh) |
| PL (1) | PL2844647T3 (zh) |
| RS (1) | RS61035B1 (zh) |
| SG (1) | SG11201407184PA (zh) |
| SI (1) | SI2844647T1 (zh) |
| WO (1) | WO2013164801A1 (zh) |
| ZA (1) | ZA201407769B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105801550B (zh) | 2009-11-05 | 2019-06-14 | 理森制药股份公司 | 新型苯并吡喃激酶调节剂 |
| SI2844647T1 (sl) * | 2012-05-04 | 2020-12-31 | Rhizen Pharmaceuticals S.A. | Postopek za pripavo optično čistih in po izbiri substituiranih derivatov 2-(1-hidroksi-alkil)-kromen-4-ona in njihova uporaba pri pripravi zdravil |
| US10130635B2 (en) * | 2012-05-04 | 2018-11-20 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals |
| WO2014195888A1 (en) | 2013-06-07 | 2014-12-11 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| SG11201610745XA (en) * | 2014-06-27 | 2017-01-27 | Rhizen Pharmaceuticals Sa | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| WO2017015221A1 (en) * | 2015-07-23 | 2017-01-26 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN108884049A (zh) | 2016-02-09 | 2018-11-23 | 法玛克亚公司 | 喹啉酮赖氨酰氧化酶样2抑制剂及其用途 |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2023130334A1 (zh) * | 2022-01-07 | 2023-07-13 | 同润生物医药(上海)有限公司 | 一种色烯-4-酮化合物及其中间体的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62201882A (ja) * | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
| PE20060426A1 (es) * | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| CN105801550B (zh) * | 2009-11-05 | 2019-06-14 | 理森制药股份公司 | 新型苯并吡喃激酶调节剂 |
| EA024842B9 (ru) | 2011-05-04 | 2017-08-31 | Ризен Фармасьютикалз Са | Соединения в качестве модуляторов протеинкиназы pi3k |
| SI2844647T1 (sl) * | 2012-05-04 | 2020-12-31 | Rhizen Pharmaceuticals S.A. | Postopek za pripavo optično čistih in po izbiri substituiranih derivatov 2-(1-hidroksi-alkil)-kromen-4-ona in njihova uporaba pri pripravi zdravil |
| MX357043B (es) * | 2012-07-04 | 2018-06-25 | Rhizen Pharmaceuticals Sa | Inhibidores selectivos de pi3k delta. |
-
2013
- 2013-05-03 SI SI201331803T patent/SI2844647T1/sl unknown
- 2013-05-03 BR BR112014027470A patent/BR112014027470A2/pt not_active Application Discontinuation
- 2013-05-03 PL PL13729095T patent/PL2844647T3/pl unknown
- 2013-05-03 MY MYPI2014003098A patent/MY171207A/en unknown
- 2013-05-03 WO PCT/IB2013/053544 patent/WO2013164801A1/en active Application Filing
- 2013-05-03 NZ NZ701198A patent/NZ701198A/en not_active IP Right Cessation
- 2013-05-03 SG SG11201407184PA patent/SG11201407184PA/en unknown
- 2013-05-03 JP JP2015509560A patent/JP6290186B2/ja not_active Expired - Fee Related
- 2013-05-03 EP EP13729095.3A patent/EP2844647B1/en active Active
- 2013-05-03 US US14/398,902 patent/US9309216B2/en not_active Expired - Fee Related
- 2013-05-03 AP AP2014008087A patent/AP3547A/xx active
- 2013-05-03 AU AU2013255469A patent/AU2013255469B2/en not_active Ceased
- 2013-05-03 CN CN201380023361.1A patent/CN104507922B/zh not_active Expired - Fee Related
- 2013-05-03 EA EA201491818A patent/EA032812B1/ru unknown
- 2013-05-03 MX MX2014013426A patent/MX365250B/es active IP Right Grant
- 2013-05-03 CN CN201810028555.5A patent/CN108084138A/zh active Pending
- 2013-05-03 RS RS20201267A patent/RS61035B1/sr unknown
- 2013-05-03 KR KR1020147034065A patent/KR102073181B1/ko active IP Right Grant
- 2013-05-03 CA CA2871000A patent/CA2871000C/en not_active Expired - Fee Related
-
2014
- 2014-10-19 IL IL235181A patent/IL235181A/en active IP Right Grant
- 2014-10-24 ZA ZA2014/07769A patent/ZA201407769B/en unknown
- 2014-11-03 PH PH12014502453A patent/PH12014502453A1/en unknown
- 2014-11-04 CL CL2014002986A patent/CL2014002986A1/es unknown
- 2014-12-03 CO CO14266920A patent/CO7141413A2/es unknown
-
2015
- 2015-05-19 HK HK15104774.7A patent/HK1203964A1/zh unknown
-
2017
- 2017-12-14 JP JP2017239643A patent/JP2018039849A/ja active Pending
-
2020
- 2020-10-15 CY CY20201100974T patent/CY1123456T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804398XA (en) | Method for producing rna molecule compositions | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| SG11201408261UA (en) | Syringe | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |